At a glance
ClinicalIndex Comparison RecordN/ACompleted· 552 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Investigation (Long-term Treatment in Patients With Rheumatoid Arthritis)
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 552 participants.
Detailed Summary
The purpose of this study was to collect data on the incidence of adverse drug reactions, infections and malignant tumors, as well as factors that might affect the safety and effectiveness of Humira® (adalimumab; 40mg/0.8 mL) in Japanese participants who received the drug for the treatment of rheumatoid arthritis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedJul 2010
Primary CompletionMay 2014
TodayJul 2026
First PostedJul 15, 2010
Enrollment StartDec 1, 2009
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.0 years ago